Phase 3 N=60 Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
Autism
Primary: ADHD Rating Scale (ADHDRS)-Home Version Total Score (Randomized Phase) — 28.7; 34.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=169 Calcium Hydroxide, Mineral Trioxide Aggregate and Biodentine (Trademark) as Direct Pulp Capping of Permanent Teeth
Caries · Dental Pulp Exposure
Primary: Parameters Evaluated After Treatment — 19; 19; 25; 3 Participants
Phase 3 N=322 Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain
Pain
Primary: Numeric Rating Scale (NRS) Summed Pain Intensity Difference (SPID) Over 0 to 48 Hours After Time 0 (NRS SPID-48) — 89.40; 171.33; 125.58; 124.85 units on a scale…
Phase 3 N=1,623 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Multiple Myeloma
Primary: Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC) — 25.5; 20.7; 21.2…
Phase 3 N=86 A Comparison of Midazolam and Zolpidem as Oral Premedication in Children
Parental/Caregiver Anxiety · Child's Anxiety
Primary: Patient Anxiety at the Time of Separation — 26.69; 30.00 units on a scale
Phase 3 N=90 First Time Use of SD-809 in Huntington Disease
Chorea
Primary: Change From Baseline (Average of Screening and Day 0) in the Average TMC Scores From Weeks 9 & 12 — -4.42; -1.93 Units on a scale — p=<0.0001
Phase 3 N=15,828 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Atherosclerosis
Primary: Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal Myocardial…
Phase 3 N=246 Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
Diffuse Large B-Cell Lymphoma
Primary: Event Free Survival — 65; 62 percentage of EFS at 3 years follow-up — p=<0.05
Phase 3 N=13,026 The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
Acute Coronary Syndrome
Primary: Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events During the Time Period for Follow-up (FU) of Cardiovascular (CV)…
Phase 3 N=445 ATLAS: Ambulatory Treatments for Leakage Associated With Stress
Stress Urinary Incontinence · Urinary Incontinence
Primary: "Much Better" or "Very Much Better" on PGI-I at 3 Months — 80; 72; 59 Participants — p=<0.0492
Phase 3 N=230 A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Sickle Cell Anemia · Sickle ß0-Thalassemia
Primary: The Number of Occurrences of Sickle Cell Crises — 3; 4 Number of crises — p=0.0052
Phase 3 N=120 Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
Preeclampsia
Primary: Increase in Gestational Age in Days — 5.0; 6.0 days
Phase 3 N=62 Borage and Echium Seed Oils for Asthma
Asthma
Primary: Cellular Changes That Occur With Borage and Echium Seed Oil Supplementation — 5.06; 2.56 ng
Phase 3 N=1,986 Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Major Depressive Disorder
Primary: Full Remission During the Randomised Treatment Period — 110; 95 participants — p=0.2641
Phase 3 N=546 To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24 — 33.7; 55.8; 60.9 percentage of…